Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

11/12/24 9:55:14 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IPSC alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 CENTURY THERAPEUTICS INC COMMON STOCK Cusip #15673T100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15673T100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,514,713 Item 6: 0 Item 7: 2,521,511 Item 8: 0 Item 9: 2,521,511 Item 11: 2.976% Item 12: HC Cusip #15673T100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,521,511 Item 8: 0 Item 9: 2,521,511 Item 11: 2.976% Item 12: IN Item 1(a). Name of Issuer: CENTURY THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 25 N 38TH STREET, 11TH FLOOR PHILADELPHIA, PA 19104 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 15673T100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,521,511 (b) Percent of Class: 2.976% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,521,511 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CENTURY THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of CENTURY THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CENTURY THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $IPSC alert in real time by email

Recent Analyst Ratings for

$IPSC

Date	Price Target	Rating	Analyst
5/27/2026	$8.00	Outperform	Mizuho
2/25/2026		Buy	TD Cowen
8/8/2024	$6.00	Buy	Rodman & Renshaw
8/28/2023	$28.00 → $5.00	Overweight → Neutral	JP Morgan
12/27/2022	$19.00	Buy	Chardan Capital Markets
10/31/2022	$15.00	Buy	Guggenheim
10/10/2022	$28.00	Buy	Canaccord Genuity
5/23/2022	$27.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

11/12/24 9:55:14 AM ET

$IPSC

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IPSC alert in real time by email

Recent Analyst Ratings for

$IPSC

Date	Price Target	Rating	Analyst
5/27/2026	$8.00	Outperform	Mizuho
2/25/2026		Buy	TD Cowen
8/8/2024	$6.00	Buy	Rodman & Renshaw
8/28/2023	$28.00 → $5.00	Overweight → Neutral	JP Morgan
12/27/2022	$19.00	Buy	Chardan Capital Markets
10/31/2022	$15.00	Buy	Guggenheim
10/10/2022	$28.00	Buy	Canaccord Genuity
5/23/2022	$27.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IPSC

Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IPSC

$IPSC
Insider Trading

President and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.84% to 3,679,786 units (SEC Form 4) to satisfy withholding tax

SVP Finance & Operations Carr Douglas sold $618 worth of shares (264 units at $2.34), decreasing direct ownership by 0.05% to 506,997 units (SEC Form 4) (for withholding tax)

SEC Form 4 filed by Murphy Martin Patrick

$IPSC
SEC Filings

SEC Form 424B7 filed by Century Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.

SEC Form SCHEDULE 13G filed by Century Therapeutics Inc.

$IPSC
Analyst Ratings

Mizuho initiated coverage on Century Therapeutics with a new price target

TD Cowen initiated coverage on Century Therapeutics

Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

$IPSC
Insider Purchases

Chief Scientific Officer Cowan Chad bought $49,252 worth of shares (58,060 units at $0.85), increasing direct ownership by 6% to 1,045,087 units (SEC Form 4)

President and CEO Pfeiffenberger Brent bought $30,352 worth of shares (52,000 units at $0.58), increasing direct ownership by 2% to 3,322,990 units (SEC Form 4)

President and CEO Pfeiffenberger Brent bought $17,328 worth of shares (35,000 units at $0.50), increasing direct ownership by 1% to 3,271,453 units (SEC Form 4)

$IPSC
Press Releases

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Century Therapeutics Reports First Quarter Financial Results and Business Updates

$IPSC
Leadership Updates

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

$IPSC
Financials

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

$IPSC
Large Ownership Changes

SEC Form SC 13G filed by Century Therapeutics Inc.